Liver Cirrhosis

• 

  Subject Areas on Research

  • A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation. 
  • A Roadmap for Value-Based Payment Models Among Patients With Cirrhosis. 
  • A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. 
  • A computer based index for the prediction of operative survival in patients with cirrhosis and portal hypertension. 
  • A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection. 
  • A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats. 
  • A man with type III glycogenosis associated with cirrhosis and portal hypertension. 
  • A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. 
  • A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease. 
  • Aberrant venous drainage to the liver: imaging implications. 
  • Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. 
  • Acetylcholine promotes the proliferation and collagen gene expression of myofibroblastic hepatic stellate cells. 
  • Actions of thrombin in the interstitium. 
  • Activation of Rac1 promotes hedgehog-mediated acquisition of the myofibroblastic phenotype in rat and human hepatic stellate cells. 
  • Activities of the hepatic enzymes of vitamin B6 metabolism for patients with cirrhosis. 
  • Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination. 
  • After goodbye? Dead hepatocytes as a biomarker for fibrosis and steatohepatitis. 
  • Aging of the Liver: What This Means for Patients with HIV. 
  • Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation. 
  • Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. 
  • Alpha-1-antitrypsin globules in hepatocytes of elderly persons with liver disease. 
  • Alterations in colonic mucosal vessels in patients with cirrhosis and noncirrhotic portal hypertension. 
  • American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. 
  • An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. 
  • Analysis of tumor characteristics and survival in liver transplant recipients with incidentally diagnosed hepatocellular carcinoma. 
  • Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver. 
  • Anchoring hepatic gene expression with development of fibrosis and neoplasia in a toxicant-induced fish model of liver injury. 
  • Antifibrotic therapies: will we ever get there? 
  • Apoptosis and cytokines in non-alcoholic steatohepatitis. 
  • Ascites in hepatitis C liver transplant recipients frequently occurs in the absence of advanced fibrosis. 
  • Assessment of liver fibrosis progression and regression by a serological collagen turnover profile. 
  • Association between puberty and features of nonalcoholic fatty liver disease. 
  • Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. 
  • Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. 
  • Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. 
  • Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. 
  • Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? 
  • Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. 
  • CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: findings simulating cirrhosis. 
  • Candida albicans cholecystitis. 
  • Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. 
  • Characterization of a canine model of glycogen storage disease type IIIa. 
  • Charges for Alcoholic Cirrhosis Exceed All Other Etiologies of Cirrhosis Combined: A National and State Inpatient Survey Analysis. 
  • Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care. 
  • Cirrhosis of the liver in long-term marrow transplant survivors. 
  • Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. 
  • Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. 
  • Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. 
  • Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. 
  • Comparison of pulsed Doppler sonography and angiography in patients with portal hypertension. 
  • Comparison of the grading of esophageal varices by transnasal endoluminal ultrasound and esophagogastroduodenoscopy. 
  • Computed tomography findings in liver fibrosis and cirrhosis. 
  • Correction of glycogen storage disease type III with rapamycin in a canine model. 
  • Correction: Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease. 
  • Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. 
  • Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. 
  • Cryosurgery after chemoembolization for hepatocellular carcinoma in patients with cirrhosis. 
  • Current management of sinusoidal portal hypertension. 
  • Current status of fibrosis markers. 
  • Cytokines and the pathogenesis of non-alcoholic steatohepatitis. 
  • DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma. 
  • Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. 
  • Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. 
  • Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. 
  • Derivation and analysis of viscoelastic properties in human liver: impact of frequency on fibrosis and steatosis staging. 
  • Detection of hepatocellular carcinoma in patients with cirrhosis: added value of coronal reformations from isotropic voxels with 64-MDCT. 
  • Developmental Morphogens & Recovery from Alcoholic Liver Disease. 
  • Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. 
  • Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. 
  • Diagnosing Liver Fibrosis and Cirrhosis: Serum, Imaging, or Tissue? 
  • Diagnosis of liver fibrosis: present and future. 
  • Diagnosis of nonalcoholic fatty liver disease. 
  • Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. 
  • Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. 
  • Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. 
  • Differential diagnosis of ascites. 
  • Disability in patients with end-stage liver disease: Results from the functional assessment in liver transplantation study. 
  • Does this patient with liver disease have cirrhosis? 
  • Donor derived HSV hepatitis in a kidney transplant recipient leading to liver fibrosis and portal hypertension. 
  • Donor-specific HLA-antibody-mediated humoral rejection in a liver transplant recipient fully reversed with plasmapheresis and immunoglobulin. 
  • Dual-Energy Multidetector Computed Tomography With Iodine Quantification in the Evaluation of Portal Vein Thrombosis: Is It Possible to Discard the Unenhanced Phase? 
  • Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. 
  • Early use of TIPS for cirrhosis and variceal bleeding. 
  • Editorial: blood biomarkers for advanced liver fibrosis in non-alcoholic fatty liver disease-not a simple choice? 
  • Editorial: platelet transfusions in cirrhosis-do the risks outweigh the unclear benefits? 
  • Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. 
  • Effect of obstructive sleep apnea on the sleep architecture in cirrhosis. 
  • Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice. 
  • Effect of varying contrast material iodine concentration and injection technique on the conspicuity of hepatocellular carcinoma during 64-section MDCT of patients with cirrhosis. 
  • Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. 
  • Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. 
  • Elaboration of tubules with active hedgehog drives parenchymal fibrogenesis in gestational alloimmune liver disease. 
  • Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. 
  • Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. 
  • Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. 
  • Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. 
  • Emergency portacaval shunts: is Orloff correct? 
  • Epigallocatechin-3-Gallate Upregulates miR-221 to Inhibit Osteopontin-Dependent Hepatic Fibrosis. 
  • Epithelial-mesenchymal transitions and hepatocarcinogenesis. 
  • Epithelial-to-mesenchymal transitions in the liver. 
  • Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. 
  • Evidence for and against epithelial-to-mesenchymal transition in the liver. 
  • Exogenous PP2A inhibitor exacerbates the progression of nonalcoholic fatty liver disease via NOX2-dependent activation of miR21. 
  • Extraocular muscle dystonia due to acquired (non-Wilsonian) hepatocerebral degeneration. 
  • Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. 
  • Factors influencing the participation of gastroenterologists and hepatologists in clinical research. 
  • Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. 
  • Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. 
  • Fate-mapping evidence that hepatic stellate cells are epithelial progenitors in adult mouse livers. 
  • Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. 
  • Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. 
  • Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications. 
  • Fine needle aspiration biopsy of the liver. 
  • Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma? 
  • Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study. 
  • From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. 
  • Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. 
  • Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease. 
  • Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. 
  • Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. 
  • Getting a "Grip" on Sarcopenia for the Liver Transplant Candidate: Time to Focus on Muscle Function. 
  • Glycogen debranching enzyme deficiency: long-term study of serum enzyme activities and clinical features. 
  • Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? 
  • Glycogen storage disease type IX: novel PHKA2 missense mutation and cirrhosis. 
  • HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. 
  • HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. 
  • Hedgehog Signaling is Associated with Liver Response to Fractionated Irradiation in Mice. 
  • Hedgehog controls hepatic stellate cell fate by regulating metabolism. 
  • Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. 
  • Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. 
  • Hedgehog-YAP Signaling Pathway Regulates Glutaminolysis to Control Activation of Hepatic Stellate Cells. 
  • Hepatic angiomyolipoma and hepatic stellate cells share a similar gene expression profile. 
  • Hepatic arterial resistive indices: correlation with the severity of cirrhosis. 
  • Hepatic complications of obesity. 
  • Hepatic complications of obesity. 
  • Hepatic fibrogenesis requires sympathetic neurotransmitters. 
  • Hepatic fibrosis associated with aging in four stocks of mice. 
  • Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. 
  • Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. 
  • Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time. 
  • Hepatitis C and depressive symptoms: psychological and social factors matter more than liver injury. 
  • Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. 
  • Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. 
  • Hepatocellular Carcinoma Surveillance. 
  • Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? 
  • Hepatocellular carcinoma in cirrhotic patients at multidetector CT: hepatic venous phase versus delayed phase for the detection of tumour washout. 
  • Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. 
  • Hepatocellular carcinoma presenting at contrast-enhanced multi-detector-row computed tomography or gadolinium-enhanced magnetic resonance imaging as a small (≤2 cm), indeterminate nodule: growth rate and optimal interval time for imaging follow-up. 
  • Hepatocellular carcinoma: clinical and angiographic findings and predictability for surgical resection. 
  • Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. 
  • Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. 
  • Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy. 
  • Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. 
  • IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. 
  • Identification and Management of Abdominal Wall Varices in Pregnancy. 
  • Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. 
  • Imaging in Patients with Cirrhosis: Current Evidence. 
  • Imaging in the preoperative evaluation of adult liver-transplant candidates: goals, merits of various procedures, and recommendations. 
  • Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. 
  • Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation. 
  • In inpatients with cirrhosis opioid use is common and associated with length of stay and persistent use post-discharge. 
  • Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. 
  • Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. 
  • Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver. 
  • Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. 
  • Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. 
  • Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. 
  • Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. 
  • Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. 
  • Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis. 
  • Intestinal transplantation: the University of Wisconsin experience. 
  • Intrahepatic landscape of regulatory T-cell subsets in chronically HCV-infected patients with cirrhosis and HCC. 
  • Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. 
  • Intrapulmonary shunt confirmed by intracardiac echocardiography in the diagnosis of hepatopulmonary syndrome. 
  • Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. 
  • Is the HCV pipeline heading in the right direction? 
  • Isolated liver transplantation in infants with total parenteral nutrition-associated end-stage liver disease. 
  • Jaundice. Value of five-day steroid test in differential diagnosis. 
  • Laparoscopic Hepatectomy for Hepatocellular Carcinoma: The Opportunities, the Challenges, and the Limitations. 
  • Laparoscopic versus open ventral hernia repair in patients with chronic liver disease. 
  • Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. 
  • Letter: are opioid prescriptions associated with hepatic encephalopathy in patients with compensated cirrhosis? Authors' reply. 
  • Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. 
  • Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. 
  • Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. 
  • Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. 
  • Liver disease in pregnancy. 
  • Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring. 
  • Liver renewal: detecting misrepair and optimizing regeneration. 
  • Liver transplantation for liver malignancies in Wilson's disease: two novel cases. 
  • Liver transplantation for the treatment of hepatocellular carcinoma. 
  • Liver transplantation. 
  • Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. 
  • Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers. 
  • Macrophage-derived Hedgehog ligands promotes fibrogenic and angiogenic responses in human schistosomiasis mansoni. 
  • Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. 
  • Mechanical pleurodesis aided by peritoneal drainage: procedure for hepatic hydrothorax. 
  • Mechanisms of Ascites Development-Reply. 
  • Mechanisms of disease progression in NASH: new paradigms. 
  • Mechanisms of disease progression in nonalcoholic fatty liver disease. 
  • Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. 
  • MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection. 
  • Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. 
  • Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. 
  • Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. 
  • Model for End-Stage Liver Disease score predicts mortality in critically ill cirrhotic patients. 
  • Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. 
  • NASH and cryptogenic cirrhosis: a histological analysis. 
  • Natural Progression of Canine Glycogen Storage Disease Type IIIa. 
  • No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. 
  • Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. 
  • Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern? 
  • Nonalcoholic Fatty Liver Disease and the Gut Microbiome. 
  • Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation. 
  • Nonalcoholic Steatohepatitis. 
  • Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context. 
  • Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. 
  • Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. 
  • Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. 
  • Noninvasive prediction of fibrosis in patients with chronic hepatitis C. 
  • Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice. 
  • One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. 
  • Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis. 
  • Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. 
  • Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis. 
  • Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. 
  • Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice. 
  • PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. 
  • PHOTON-2: hope for patients with HIV and HCV co-infection? 
  • Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. 
  • Paracrine modulation of cholangiocyte serotonin synthesis orchestrates biliary remodeling in adults. 
  • Paraparesis, hypermanganesaemia, and polycythaemia: a novel presentation of cirrhosis. 
  • Pathology and imaging of hepatocellular neoplasms: are findings from Asian populations applicable to non-Asian groups? 
  • Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. 
  • Performance of the AST-to-platelet ratio index as a noninvasive marker of fibrosis in pediatric patients with chronic viral hepatitis. 
  • Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. 
  • Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. 
  • Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. 
  • Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis. 
  • Portacaval shunts for ascites: another perspective. 
  • Portal hypertensive stomapathy: a newly described entity and its successful treatment by placement of a transjugular intrahepatic portosystemic shunt. 
  • Portosystemic shunts in children: a 15-year experience. 
  • Potential role of Hedgehog signaling and microRNA-29 in liver fibrosis of IKKβ-deficient mouse. 
  • Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases. 
  • Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. 
  • Prognosis of patients with cirrhosis and chronic liver disease admitted to the medical intensive care unit. 
  • Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. 
  • Providing primary care for long-term survivors of childhood acute lymphoblastic leukemia. 
  • Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. 
  • Quantifying hepatic shear modulus in vivo using acoustic radiation force. 
  • Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. 
  • Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center. 
  • Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. 
  • Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease. 
  • Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. 
  • Relationship of Liver Stiffness With Congestion in Patients Presenting With Acute Decompensated Heart Failure. 
  • Relationship of smoking and fibrosis in patients with chronic hepatitis C. 
  • Reply: To PMID 24123276. 
  • Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. 
  • Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. 
  • Retransplantation of the liver--a seven-year experience. 
  • Retrodisplaced gallbladder detected on hepatobiliary scintigraphy. 
  • Retrospective clinicopathologic correlation of gross tumor size of hepatocellular carcinoma: implications for stereotactic body radiotherapy. 
  • Reversible cardiomyopathies--a review. 
  • Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. 
  • Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. 
  • Risks of a range of alcohol intake on hepatitis C-related fibrosis. 
  • Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis. 
  • Role of computed tomography in screening for hepatocellular carcinoma in patients with cirrhosis. 
  • Role of inflammation in nonalcoholic steatohepatitis. 
  • Routine laparoscopy in the management of chronic hepatitis. 
  • STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. 
  • Safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety). 
  • Schistosome-induced cholangiocyte proliferation and osteopontin secretion correlate with fibrosis and portal hypertension in human and murine schistosomiasis mansoni. 
  • Serum osteopontin is a biomarker of severe fibrosis and portal hypertension in human and murine schistosomiasis mansoni. 
  • Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. 
  • Signals from dying hepatocytes trigger growth of liver progenitors. 
  • Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. 
  • Smoothened is a master regulator of adult liver repair. 
  • Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. 
  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. 
  • Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. 
  • Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. 
  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. 
  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. 
  • Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent. 
  • Spectrum of Pitfalls, Pseudolesions, and Potential Misdiagnoses in Cirrhosis. 
  • Splenorenal shunt with underlying cirrhosis of the liver. 
  • Staphylococcus aureus pericardial abscess in a patient with liver cirrhosis: case report. 
  • Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. 
  • Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. 
  • Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. 
  • Streptococcus equi primary bacteremia in a hepatitis-C cirrhotic patient. 
  • Surveillance for hepatocellular carcinoma. 
  • Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice. 
  • Sympathetic nervous system regulation of liver repair. 
  • Temporal trends in U. S. multiple cause of death mortality data: 1968 to 1977. 
  • The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. 
  • The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. 
  • The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. 
  • The clinical management of HCV in the HIV-infected patient. 
  • The coagulation cascade in cirrhosis. 
  • The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. 
  • The course of hepatic cirrhosis. 
  • The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 
  • The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. 
  • The hedgehog pathway in nonalcoholic fatty liver disease. 
  • The hepatopulmonary syndrome: radiologic findings in 10 patients. 
  • The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. 
  • The natural history of hepatitis C viral infection. 
  • The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. 
  • The pathology of primary biliary cirrhosis. 
  • The prevalence and etiology of elevated aminotransferase levels in the United States. 
  • The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. 
  • The rational clinical examination. Does this patient have ascites? How to divine fluid in the abdomen. 
  • The role of Hedgehog signaling in fibrogenic liver repair. 
  • The role of endoscopy in the management of variceal hemorrhage. 
  • Transjugular intrahepatic portosystemic shunt in patients with end-stage liver disease: results in 85 patients. 
  • Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. 
  • Transplantation-mediated alloimmune thrombocytopenia: Guidelines for utilization of thrombocytopenic donors. 
  • Two cases from the spectrum of nonalcoholic steatohepatitis. 
  • Underlying potential: cellular and molecular determinants of adult liver repair. 
  • Understanding the Complexities of Cirrhosis. 
  • Unique characteristics of cryptococcosis identified after death in patients with liver cirrhosis: comparison with concurrent cohort diagnosed antemortem. 
  • Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. 
  • Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia. 
  • Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. 
  • Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. 
  • Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients. 
  • Vibration-Controlled Transient Elastography for Diagnosing Cirrhosis and Staging Hepatic Fibrosis. 
  • Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. 
  • Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. 
  • Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. 
  • Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. 
  • Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model. 
  • Volume-mediated pulmonary responses in liver transplant candidates. 
  • WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. 
  • Watchful waiting: role of disease progression on uncertainty and depressive symptoms in patients with chronic hepatitis C. 
  • Without victory there is no survival: transarterial lipiodol chemoembolization and hepatocellular carcinoma. 
  • [THE ENZYMES OF THE LEUKOCYTE]. 
• 

  Keywords of People

  • Choi, Steven Sok, Associate Professor of Medicine, Medicine, Gastroenterology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Yancy Jr., William Samuel, Associate Professor of Medicine, Medicine, General Internal Medicine